 This has been disseminated on behalf of Oncolytics Biotech. FDA Fast Track Energy is Building Around Oncolytics Biotech (NASDAQ: ONCY): The Cancer Immunotherapy Play Fighting for Wall Street Attention! Small biotech names can go from ignored to headline makers overnight when the right catalyst hits and Oncolytics Biotech (NASDAQ: ONCY) is putting together a serious list of reasons why you should look twice. The company just scored another major win with FDA Fast Track designation for pelareorep in advanced anal cancer, marking another regulatory milestone that strengthens its position in the race toward potential registration. ONCY is not just chasing one opportunity; it’s building a broader immunotherapy platform with multiple shots on goal! The momentum is coming together fast. ONCY has FDA engagement, Fast Track status across gastrointestinal cancer programs, encouraging clinical data, expanding trial activity, and intellectual property protection designed to support the long game. Pelareorep is being developed as an immune-activating therapy that could potentially help make difficult-to-treat tumors more responsive, opening doors across colorectal, anal, pancreatic, and other cancer indications. With catalysts lining up and regulatory conversations heating up, ONCY is becoming a biotech ticker that deserves a spot on the watchlist! The FDA Fast Track momentum is heating up. Learn why ONCY could be entering a major turning point!
More Reading from MarketBeat
Why SK hynix Could Be the Best AI Chip Stock to Buy NowReported by Thomas Hughes. Article Published: 7/29/2026. 
Key Points
- Analysts remain bullish on SK hynix despite a Q2 revenue miss, citing strong margin growth and over 100% upside potential across coverage.
- SK Hynix is expanding capacity through a major NVIDIA deal and doubling wafer output, driven by surging AI-related HBM and DRAM demand.
- Risks include execution and competition from Micron, but analysts argue the AI-driven memory upswing is structural and still in its early stages.
- Special Report: Sell these "safe" blue chips immediately
Given SK hynix’s (NASDAQ: SKHY) dominant position in digital memory—particularly high-bandwidth memory (HBM)—the stock is a good one to own and perhaps one of the best for 2026 and the next several years. The biggest risk for U.S. investors is the hype and premium attached to the recently listed American Depository Receipts (ADRs), which have impaired the risk/reward profile. As July comes to an end, however, the premium is eroding, opening the buying opportunity that smart money has been waiting for. Analysts Stay Bullish on SK hynix Despite the Q2 Miss
Analyst sentiment remains firm, pointing to significant upside for the stock in both the South Korean market and the ADRs. Sentiment was not impaired by weakness in Q2 earnings. The weaknesses were linked to timing, product mix and shifts such as the launch of next-generation HBM products, which are scheduled to ramp in the second half of the year. Analyst coverage of SKHY on MarketBeat is limited, with only three analysts tracked, but it is robust when combined with coverage of the South Korean market. Together, the 40 current reports reflect a Moderate Buy/Strong Buy consensus and indicate more than 100% upside potential. Consensus among U.S.-listed coverage suggests 150% upside, a target echoed in coverage of competitor Micron (NASDAQ: MU). SK hynix Misses a High Bar With a Robust QuarterSK hynix missed consensus revenue estimates, but the bar was set high. All analysts had raised their targets since the last report, while whispers suggested growth of as much as 300% was possible. The critical details from the release include a 257% year-over-year increase, sequential acceleration and the margin strength that followed. Top-line results were underpinned by AI, with DRAM and HBM pricing compounding volume gains. Other end markets, including PCs and smartphones, were less robust but remain supply-constrained, a situation expected to improve over time. 
SK hynix, aided by capital raised through its U.S. listing, aims to double its chip wafer capacity within the next five years. A deal with NVIDIA (NASDAQ: NVDA) is also in play, with the goal of scaling capacity across multiple production clusters to support AI infrastructure needs. Valued at more than $500 billion, the deal also secured years of future memory supply, cementing SK hynix’s growth trajectory and pricing power. Q2 margin news was stellar. Surging demand, pricing power and capacity utilization drove margin gains down the stack. The critical details were the 557% increase in operating profit and the guidance, which noted increasing and broadening demand tied to high-performance computing and inference needs. The company also mentioned 10 new long-term agreements with hyperscale clients, confirming a structural shift in the memory market. Memory is no longer a niche market constrained by quarterly pricing fluctuations; it is a critical piece of digital infrastructure commanding multiyear contracts and greater price stability. SK hynix’s Biggest Risks? Execution and CompetitionSK hynix’s biggest risks are execution and competition. Supply constraints, capacity expansion and the risk of oversupply could limit growth prospects and set the market up for a massive correction. At the same time, competitors such as Micron are working hard to capture market share while expanding capacity to meet demand, threatening SK hynix’s future growth and increasing the risk of market oversupply. The caveat is that AI spending plans have yet to be curtailed, leaving the fundamental story intact. Signs suggest the AI memory upswing is only beginning. This year’s catalysts include product launches. HBM4 began shipping in Q2, but the product ramp is slated for the second half of the year, which will unlock capacity in the GPU supply chain. HBM4 is critical to Vera Rubin production, which, in turn, is critical to AI data center buildout. Oracle’s (NYSE: ORCL) contracts, for example, are heavily back-ended and dependent on capacity and computing power that have yet to be unleashed. Other launches include industry-specific solutions for mobility and personal computing, which are forecast to drive growth. AI Memory Demand Is Structural, Not CyclicalWhat the market gets wrong about SK hynix and other memory leaders is that AI is not a typical cyclical blip in the memory chip demand cycle. It is a structural shift that is gaining momentum. While the push for training infrastructure may slow, it is giving way to inference, which requires exponentially more memory. Each query requires a new memory dump, and the number of queries is growing daily as the models become more complex. The takeaway is that the memory cycle isn’t ending, as some fear; it is in its earliest phases and could accelerate over the next few quarters. Dividends, Buybacks, and a Cash Flow StoryInvestors can also benefit from SK hynix’s cash flow. The company is committed to capital returns, paying a baseline dividend with contingencies to increase payments as income improves. The Q2 release reaffirmed that commitment and raised the stakes, indicating an intention to accelerate returns, potentially through share buybacks. ADR holders are entitled to a proportional share of distributions, which are expected to be paid each quarter.
This message is a paid advertisement for Oncolytics Biotech Inc. (NASDAQ: ONCY) from Equiscreen and Organized Noise. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $14,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Equiscreen or Organized Noise. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Oncolytics Biotech Inc. (NASDAQ: ONCY) on Organized Noise' website for additional information about the relationship between Organized Noise and Oncolytics Biotech Inc. (NASDAQ: ONCY).
. |
Comments
Post a Comment